The Administrative Core is the central command and operations post of the Liver Pathobiology and Gene Therapy Research Core Center. The Core maintains and manages the fundamental infrastructure necessary to sustain and strengthen basic translational and clinical liver-related research at the Center. All planning, communications and activities of the Center go through this office. Dr. Allan W. Wolkoff, Director of the Center is Director of the Administrative Core. He is assisted by the Associate Director, David A. Shafritz, who oversees operation of the Research Core Facilities and our Administrator, who manages the Core Center grant and grants submitted by Center Investigators. She assists in preparation of all budgets and personnel assigned to grants flowing through the Center;in addition, she manages expenditures by the Core Facilities, Pilot and Feasibility Studies and the Enrichment Program. Four key committees, 1) the Executive Committee, 2) the Scientific Advisory Committee, 3) the Core Facilities Management Committee and the 4) Educational and Enrichment Committee work to ensure smooth operations of the Center and assure outstanding program management and effective operation. Working together, under the outstanding vision and leadership of the Director, and with continued support from NIDDK, Albert Einstein College of Medicine and Montefiore Medical Center, the Pathobiology and Gene Therapy Research Core Center enthusiastically looks forward to achieving major advances in liver pathobiology and treatment of liver diseases, during the next funding period.
It is estimated that over 30 million Americans have a liver disorder;further, liver disease is one of the ten leading causes of death in the United States. Although advances have been made in diagnosis and treatment of liver diseases, there is still much to be learned. The Liver Research Center at Einstein provides a multidisciplinary approach to the study of liver disease by integrating basic and clinical research efforts to foster development of new insights and paradigms.
|Soltys, Kyle A; Setoyama, Kentaro; Tafaleng, Edgar N et al. (2017) Host conditioning and rejection monitoring in hepatocyte transplantation in humans. J Hepatol 66:987-1000|
|Jaber, Fadi Luc; Sharma, Yogeshwar; Gupta, Sanjeev (2017) Demonstrating Potential of Cell Therapy for Wilson's Disease with the Long-Evans Cinnamon Rat Model. Methods Mol Biol 1506:161-178|
|Wijetunga, N A; Pascual, M; Tozour, J et al. (2017) A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene 36:2030-2044|
|Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Listowsky, Irving et al. (2017) Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir. Clin Pharmacol Drug Dev 6:140-146|
|Akiyama, Matthew J; Kaba, Fatos; Rosner, Zachary et al. (2017) Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System. Public Health Rep 132:41-47|
|Shen, Ling; Wang, David Q H; Xu, Meifeng et al. (2017) BDNF/TrkB signaling mediates the anorectic action of estradiol in the nucleus tractus solitarius. Oncotarget 8:84028-84038|
|Arvans, Donna; Jung, Yong-Chul; Antonopoulos, Dionysios et al. (2017) Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. J Am Soc Nephrol 28:876-887|
|Zhao, H; Lu, Z; Bauzon, F et al. (2017) p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene 36:60-70|
|Rogler, Charles E; Bebawee, Remon; Matarlo, Joe et al. (2017) Triple Staining Including FOXA2 Identifies Stem Cell Lineages Undergoing Hepatic and Biliary Differentiation in Cirrhotic Human Liver. J Histochem Cytochem 65:33-46|
|Maus, Mate; Cuk, Mario; Patel, Bindi et al. (2017) Store-Operated Ca2+ Entry Controls Induction of Lipolysis and the Transcriptional Reprogramming to Lipid Metabolism. Cell Metab 25:698-712|
Showing the most recent 10 out of 399 publications